Table 3

Comparison of Moderate and Low Doses ofICSs in Terms of Local Adverse Events and Withdrawal Because of Adverse Effects

StudyICSModerate vs Low Doses, μg/dAdverse Events, No. of Events/No. of Patients; RR (95% CI)
WithdrawalsOral CandidiasisDysphonia/HoarsenessCoughPharyngitis/Sore Throat
Allen et al15 (1998)FLU Diskhaler200 vs 1001/108 vs 0/111; 3.08 (0.13, 74.85)1/108 vs 3/111; 0.34 (0.04–3.24)0/108 vs 3/111; 0.15 (0.01–2.81)4/108 vs 3/111; 1.37 (0.31–5.98)1/108 vs 4/111; 0.26 (0.03–2.26)
Katz et al14 (1998)FLU DPI200 vs 1004/87 vs 5/85; 0.79 (0.22–2.84)2/87 vs 1/85; 1.95 (0.18–21.15)3/87 vs 0/85; 6.84 (0.36–130.47)0/87 vs 1/85; 0.32 (0.01–7.89)
Shapiro et al48 (1998b)BUD Turbuhaler400 vs 2001/100 vs 0/102; 3.06 (0.13–74.22)
Peden et al16 (1998)FLU DPI200 vs 1001/170 vs 3/170; 0.40 (0.15–1.11)
Shapiro et al12 (2001)BUD Turbuhaler400 vs 2004/93 vs 5/90; 0.77 (0.21–2.79)6/93 vs 4/90; 1.45 (0.42–4.97)
Nayak et al13 (2002)BDP HFA Autohaler160 vs 801/117 vs 1/120; 1.03 (0.06–16.21)9/117 vs 7/120; 1.32 (0.51–3.42)9/117 vs 13/120; 0.71 (0.32–1.60)
Berger et al44 (2006)MOM DPI200 vs 1000/99 vs 0/985/99 vs 9/98; 0.55 (0.19–1.58)
Gelfand et al45 (2006)CIC HFA MDI160 vs 40–8016/253 vs 41/515; 0.79 (0.45–1.39)2/253 vs 1/515; 4.07 (0.37–44.69)14/253 vs 22/515; 1.14 (0.70–1.86)
Skoner et al17 (2008)CIC HFA MDI160 vs 408/219 vs 14/221; 0.58 (0.25–1.35)0/219 vs 0/2210/219 vs 0/22137/219 vs 44/221; 0.85 (0.57–1.26)
Pedersen et al46 (2009)CIC HFA MDI160 vs 801/242 vs 0/252; 3.12 (0.13–76.30)
FLIP3951FLU DPI200 vs 1002/99 vs 6/97; 0.33 (0.07–1.58)1/99 vs 1/97; 0.98 (0.06–15.40)3/99 vs 1/97; 2.94 (0.31–27.77)1/99 vs 3/97; 0.33 (0.04–3.09)
Pooled result7/1108 vs 5/1384; 1.65 (0.52–5.25)4/513 vs 4/514; 0.99 (0.12–8.33)16/411 vs 12/413; 1.35 (0.65–2.81)73/988 vs 99/1252; 0.88 (0.67–1.45)
  • RR indicates risk ratio; FLU, fluticasone; BUD, budesonide; HFA, hydrofluoroalkane; MOM, mometasone; CIC, ciclesonide; —, not available/applicable.